Search Result

Results for "

calcium assay

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (3) Calcium Channel (4) Autophagy (1) CaMK (1) Cannabinoid Receptor (1) CCR (3) CXCR (3) Dopamine Receptor (1) Endogenous Metabolite (1) Formyl Peptide Receptor (FPR) (2) GPR84 (1) Interleukin Related (1) mGluR (3) NOD-like Receptor (NLR) (1) Phosphodiesterase (PDE) (1) Syk (1) TREM receptor (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (8) Metabolic Disease (4) Neurological Disease (8)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Targets Recommended: Biochemical Assay Reagents Calcium Channel CaSR Calmodulin Calpain CRAC Channel PNPLA3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128121

MLS1547	Dopamine Receptor	Neurological Disease
MLS1547 is a highly efficacious G protein-biased dopamine D2 receptor (D2R) agonist (K_i=1.2 μM). MLS1547 stimulates D2R G protein-mediated signaling (EC₅₀=0.37 μM in a calcium mobilization assay). MLS1547 acts as an antagonist for dopamine (DA)-stimulated β-arrestin recruitment to the D2R (IC₅₀=9.9 μM) .

HY-103318

PD173212 3 Publications Verification	Calcium Channel	Neurological Disease
PD173212 is a selective *N-type voltage sensitive calcium* channel (VSCC) blocker, with an IC₅₀** of 36 nM in IMR-32 assays.

HY-110190

VU0422288 ML396	mGluR	Neurological Disease
VU0422288 (ML396) is a positive allosteric modulator of group III mGluRs. VU0422288 inhibits mGluRs with EC₅₀s of 125 nM, 146 nM, and 108 nM for mGluR4, mGluR7, and mGluR8, respectively in calcium mobilization assays. VU0422288 reverses deficits in contextual fear memory, social recognition, and apneas in Rett syndrome (RTT) model mice .

HY-P0225

Autocamtide 2 Autocamtide II	CaMK Autophagy	Neurological Disease
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.

HY-131349

CCR4-351	CCR	Cancer
CCR4-351 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC₅₀s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity .

HY-145697

GPR84 antagonist 2	GPR84	Inflammation/Immunology
GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC₅₀=8.95 nM). GPR84 antagonist 2 shows improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. GPR84 antagonist 2 has the potential for the research of ulcerative colitis .

HY-124759

CCR1 antagonist 9	CCR	Inflammation/Immunology
CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC₅₀ of 6.8 nM in calcium flux assay .

HY-137672A

2',3'-Cyclic NADP disodium 2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate	Phosphodiesterase (PDE) Calcium Channel	Neurological Disease
2',3'-Cyclic NADP disodium (2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate) is a substrate for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), an enzyme abundant in myelin. It has been used in a coupled enzyme assay to quantify CNP activity. 2',3'-Cyclic NADP disodium (5 μM) increases calcium overload-induced calcium release and prevents calcium-induced swelling in rat brain mitochondria.

HY-P2355

BOC-FlFlF BOC2; Boc-Phe-dLeu-Phe-dLeu-Phe	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
BOC-FlFlF (Boc-Phe-dLeu-Phe-dLeu-Phe) is a selective FPR1 antagonist. Boc-FlFlF has an apparent dissociation constant (K_D) of 230 nM as determined by the intracellular calcium mobilization assay. Boc-FlFlF can be used for the study of inflammation .

HY-100310

N-type calcium channel blocker-1	Calcium Channel	Neurological Disease
N-type calcium channel blocker-1 is an orally active compound which shows high affinity to functionally block *N-type calcium* channels with an IC₅₀** of 0.7 μM in the IMR32 assay.

HY-153132

mGluR3 modulator-1	mGluR	Metabolic Disease
mGluR3 modulator-1 (compound 3) is a mGluR3 modulator, with an EC₅₀ of 1-10 μM in HEK293T-mGluR-Gqi5 Calcium Mobilization Assay .

HY-131349A

CCR4-351 hydrochloride	CCR	Metabolic Disease Cancer
CCR4-351 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4-351 hydrochloride, featuring a novel piperidinyl-azetidine motif, has IC₅₀s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 hydrochloride has antitumor activity .

HY-179024

NP3-742	NOD-like Receptor (NLR) Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
NP3-742 is an orally active NLRP3 inhibitor that binds to the NLRP3 NACHT domain. NP3-742 inhibits IL-1β release with IC₅₀s of 6 nM and 47 nM in both the cellular and whole blood assays, respectively. NP3-742 is highly selective against a panel of more than 50 enzymes, receptors and sodium and calcium channels. NP3-742 can be used for the study of gout, cardiovascular disease or osteoarthritis .

HY-166984

Phytic acid calcium	Biochemical Assay Reagents	Others
Phytic acid (calcium) is a biochemical assay reagent.

HY-W505389

Calcium D-saccharate	Biochemical Assay Reagents	Others
Calcium D-saccharate is a biochemical assay reagent.

HY-W795652

Calcium α-D-heptagluconate hydrate	Biochemical Assay Reagents	Others
Calcium α-D-heptagluconate hydrate is a biochemical assay reagent.

HY-111332

(E)-PHCCC	mGluR	Others
(E)-PHCCC is a positive allosteric modulator (PAM) for mGluR4, that enhances the activity of the receptor's endogenous ligand (glutamate), and exhibits activity in the calcium mobilization assay in CHO cells with an EC₅₀ of 3.2 μM .

HY-P2355A

BOC-FlFlF TFA BOC2 TFA; Boc-Phe-dLeu-Phe-dLeu-Phe TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
BOC-FlFlF (TFA) (Boc-Phe-dLeu-Phe-dLeu-Phe (TFA)) is a selective FPR1 antagonist. BOC-FlFlF has an apparent dissociation constant (K_D) of 230 nM as determined by the intracellular calcium mobilization assay. BOC-FlFlF can be used for the study of inflammation .

HY-144784

CXCR2 antagonist 7	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist. CXCR2 antagonist 7 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144783

CXCR2 antagonist 6	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144781

CXCR2 antagonist 5	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC₅₀=0.013 µM) and calcium mobilization (IC₅₀=0.1 µM) ^{[ 1]}.

HY-14232

TTA-A8	Calcium Channel	Neurological Disease
TTA-A8 (Compound 13) is a short-acting *T-type calcium* channel** antagonist with oral activity, exhibiting an IC₅₀ value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep .

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-182697

RTICBM-74	Cannabinoid Receptor	Metabolic Disease
RTICBM-74 is a blood-brain barrier-permeable, selective CB1 allosteric modulator with IC₅₀ values of 23 nM (calcium mobilization assay) and 153 nM ([ ³⁵S]GTPγS assay). RTICBM-74 inhibits CB1 receptor signaling. RTICBM-74 reduces alcohol intake in rats. RTICBM-74 can be used for the research of alcohol use disorder .

HY-182702

As48	TREM receptor Syk	Neurological Disease
As48 is a selective TREM2 agonist with a K_D value of 12.48 μM in TRIC binding assay. As48 binds near the TREM2 cleavage region, forms hydrogen bonds with Gly68, reduces conformational flexibility in regions 58-102, restricts protease accessibility to the cleavage site. As48 activates SYK phosphorylation, enhances microglial phagocytosis, and induces downstream calcium signaling in TREM2-expressing cells. As48 inhibits TREM2 ectodomain shedding without affecting ADAM10/17 protease activities. As48 can be used for the research of Alzheimer's disease .

Phytic acid calcium	Biochemical Assay Reagents
Phytic acid (calcium) is a biochemical assay reagent.

Calcium D-saccharate	Biochemical Assay Reagents
Calcium D-saccharate is a biochemical assay reagent.

Calcium α-D-heptagluconate hydrate	Biochemical Assay Reagents
Calcium α-D-heptagluconate hydrate is a biochemical assay reagent.

Cat. No.	Product Name	Target	Research Area

HY-P0225

Autocamtide 2 Autocamtide II	CaMK Autophagy	Neurological Disease
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.

HY-P2355

BOC-FlFlF BOC2; Boc-Phe-dLeu-Phe-dLeu-Phe	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
BOC-FlFlF (Boc-Phe-dLeu-Phe-dLeu-Phe) is a selective FPR1 antagonist. Boc-FlFlF has an apparent dissociation constant (K_D) of 230 nM as determined by the intracellular calcium mobilization assay. Boc-FlFlF can be used for the study of inflammation .

HY-P2355A

BOC-FlFlF TFA BOC2 TFA; Boc-Phe-dLeu-Phe-dLeu-Phe TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
BOC-FlFlF (TFA) (Boc-Phe-dLeu-Phe-dLeu-Phe (TFA)) is a selective FPR1 antagonist. BOC-FlFlF has an apparent dissociation constant (K_D) of 230 nM as determined by the intracellular calcium mobilization assay. BOC-FlFlF can be used for the study of inflammation .

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.